Table 2 Comparison of the two groups of patients in terms of demographic and preoperative characteristics
From: Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma
|  | Bilirubin ≤75 μmol/L (n = 82) | Bilirubin > 75 μmol/L (n = 8) | P value |
|---|---|---|---|
Age (years) | 66.0 (29–85) | 69.0 (56–72) | 0.696 |
Male: Female | 55: 27 | 8: 0 | 0.125 |
Comorbidity | 38 (46.3%) | 3 (37.5%) | 0.914 |
 Heart | 35 (42.7%) | 2 (25%) | 0.553 |
 Lung | 5 (6.1%) | 1 (12.5%) | 1.000 |
 Renal | 1 (1.2%) | 0 (0%) | 1.000 |
 Diabetes mellitus | 15 (18.3%) | 1 (12.5%) | 1.000 |
Child-Pugh class | Â | Â | 0.159 |
 A | 37 (45.1%) | 1 (12.5%) |  |
 B | 45 (54.9%) | 7 (87.5%) |  |
Pre-drainage bilirubin (μmol/L) | 98.0 (8–576) | 124.0 (28–492) | 0.673 |
Post-drainage bilirubin (μmol/L) | 20.5 (7–73) | 95.5 (76–366) | < 0.001a |
Creatinine (μmol/L) | 76.5 (40–148) | 81.0 (61–130) | 0.391 |
Albumin (g/L) | 37.0 (27–51) | 37.0 (26–43) | 0.312 |
International normalized ratio | 1.0 (0.9–1.4) | 1.0 (0.9–1.2) | 0.473 |
Platelet count (× 109/L) | 288.0 (71–561) | 342.0 (166–699) | 0.750 |
Carcinoembryonic antigen (ng/mL) | 2.65 (0.3–16) | 3.0 (1.8–10.0) | 0.528 |
Indocyanine green retention rate at 15 min (%) (n = 38) | 10.55 (3–20.1) | 20.6 (7.9–32.5) | 0.148 |
Aspartate transaminase (U/L) | 71.5 (14–748) | 56.5 (45–337) | 0.771 |
Alanine transaminase (U/L) | 101.5 (9–1178) | 106.0 (37–481) | 0.837 |
Neoadjuvant chemotherapy | 1 (1.6%) | 0 (0%) | 1.000 |
Portal vein embolization | 28 (34.1%) | 2 (25.0%) | 0.896 |
Time from drainage procedure to hepatectomy (months) | 1.84 (0.2–4.7) | 1.35 (0.3–3.1) | 0.772 |
ERCP | 69 (84.1%) | 7 (87.5%) | 1.000 |
ERCP purpose | Â | Â | 0.939 |
 No | 13 (15.9%) | 1 (12.5%) |  |
 Diagnosis | 53 (64.6%) | 5 (62.5%) |  |
 Complication | 1 (1.2%) | 0 (0%) |  |
 Diagnosis + Complication | 15 (18.3%) | 2 (25%) |  |
ERCP complication | Â | Â | 0.615 |
 No | 57 (69.5%) | 6 (75%) |  |
 Cholangitis | 10 (12.2%) | 2 (25%) |  |
 Pancreatitis | 11 (13.4%) | 0 (0%) |  |
 Deranged liver function tests | 2 (2.4%) | 0 (0%) |  |
 Slip | 1 (1.2%) | 0 (0%) |  |
 Cholangitis + Pancreatitis | 1 (1.2%) | 0 (0%) |  |
PTBD | 49 (59.8%) | 5 (62.5%) | 1.000 |
PTBD purpose | Â | Â | 0.755 |
 No | 34 (41.5%) | 3 (37.5%) |  |
 Diagnosis | 30 (36.6%) | 4 (50%) |  |
 Complication | 4 (4.9%) | 0 (0%) |  |
 Diagnosis + Complication | 14 (17.1%) | 1 (12.5%) |  |
PTBD complication | Â | Â | 0.722 |
 No | 66 (80.5%) | 7 (87.5%) |  |
 Cholangitis | 4 (4.9%) | 1 (12.5%) |  |
 Cholecystitis | 1 (1.2%) | 0 (0%) |  |
 Severe pancreatitis precluding management | 1 (1.2%) | 0 (0%) |  |
 Slip | 6 (7.3%) | 0 (0%) |  |
 Cholangitis + Slip | 4 (4.9%) | 0 (0%) |  |